Po­sei­da pro­motes cell ther­a­py pres­i­dent to CEO; Af­ter IPO, Neumo­ra ap­points R&D chief

→ The CEO post is chang­ing hands once again at Po­sei­da, as Kristin Yare­ma gets pro­mot­ed to the top spot on Jan. 1 and Mark Ger­gen will take on the role of ex­ec­u­tive chair­man. At the con­clu­sion of her sev­en years with Am­gen (2013-20), Yare­ma was bumped up to VP & ther­a­peu­tic area head for glob­al prod­uct strat­e­gy & com­mer­cial in­no­va­tion in hema­tol­ogy-on­col­o­gy. She then spent more than two years at Atara Bio­ther­a­peu­tics as com­mer­cial chief be­fore be­com­ing pres­i­dent of cell ther­a­py at Po­sei­da in April. Ger­gen, the for­mer CBO at the San Diego CAR-T biotech, suc­ceed­ed Er­ic Os­tertag as chief ex­ec­u­tive on Feb. 1, 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.